Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.32B |
| 2 |
AstraZeneca
AZN
|
+$733M |
| 3 |
Microsoft
MSFT
|
+$728M |
| 4 |
Cadence Design Systems
CDNS
|
+$720M |
| 5 |
Moody's
MCO
|
+$359M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$1.43B |
| 2 |
Estee Lauder
EL
|
+$872M |
| 3 |
Eli Lilly
LLY
|
+$626M |
| 4 |
Netflix
NFLX
|
+$521M |
| 5 |
UnitedHealth
UNH
|
+$466M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.19% |
| 2 | Consumer Discretionary | 19.62% |
| 3 | Healthcare | 16.16% |
| 4 | Financials | 9.12% |
| 5 | Communication Services | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Hexcel
HXL
$7.91B
| $53.3M | 0.05% |
780,302
+525,820
| +207% | +$35.7M |
|
|
RVNC
177
DELISTED
Revance Therapeutics, Inc.
RVNC
| $52.6M | 0.05% |
1,633,305
-392,720
| -19% | -$12.2M |
|
178
Halliburton
HAL
$27B
| $52.3M | 0.05% |
1,653,897
+45,093
| +3% | +$1.67M |
|
179
Progyny
PGNY
$2.47B
| $51.3M | 0.05% |
1,597,160
-933,807
| -37% | -$30.8M |
|
180
Syndax Pharmaceuticals
SNDX
$1.73B
| $51M | 0.05% |
2,416,454
+114,208
| +5% | +$2.84M |
|
|
PLYM
181
DELISTED
Plymouth Industrial REIT
PLYM
| $50.4M | 0.05% |
2,401,126
+228,512
| +11% | +$4.81M |
|
182
Burlington
BURL
$23.1B
| $50.4M | 0.05% |
249,140
+132,829
| +114% | +$29M |
|
|
LADR
183
Ladder Capital
LADR
$1.23B
| $50.3M | 0.05% |
5,325,318
+1,016,191
| +24% | +$10.8M |
|
184
Clear Secure
YOU
$5.57B
| $50.2M | 0.05% |
1,919,797
+21,101
| +1% | +$599K |
|
185
Darling Ingredients
DAR
$9.57B
| $50.2M | 0.05% |
859,360
+31,883
| +4% | +$2M |
|
186
Teledyne Technologies
TDY
$31.7B
| $49.3M | 0.05% |
110,298
+70
| +0.1% | +$29.7K |
|
187
Ryan Specialty Holdings
RYAN
$5.74B
| $48.8M | 0.04% |
1,212,226
-75,636
| -6% | -$3.11M |
|
188
Herc Holdings
HRI
$5.73B
| $48.5M | 0.04% |
425,792
+264,348
| +164% | +$36.5M |
|
189
Toll Brothers
TOL
$14.4B
| $48.4M | 0.04% |
807,080
-4,064
| -0.5% | -$234K |
|
190
Markel Group
MKL
$23.4B
| $48.3M | 0.04% |
+37,830
| New | +$50.3M |
|
191
Constellium
CSTM
$4.01B
| $47.8M | 0.04% |
3,129,025
+3,021,995
| +2,824% | +$44M |
|
|
INN
192
Summit Hotel Properties
INN
$746M
| $47.8M | 0.04% |
6,825,650
+90,752
| +1% | +$688K |
|
193
GE Aerospace
GE
$391B
| $46.6M | 0.04% |
+610,728
| New | +$40.9M |
|
194
Vistra
VST
$49B
| $46.5M | 0.04% |
1,936,565
+462,029
| +31% | +$10.7M |
|
195
Independence Realty Trust
IRT
$4.01B
| $46.2M | 0.04% |
2,881,702
-604,185
| -17% | -$10.6M |
|
196
Quanta Services
PWR
$105B
| $46.1M | 0.04% |
276,619
-35,929
| -11% | -$5.52M |
|
197
HubSpot
HUBS
$12.7B
| $45.9M | 0.04% |
107,104
-553,581
| -84% | -$202M |
|
198
Plains GP Holdings
PAGP
$5.05B
| $45.6M | 0.04% |
3,474,054
| – | – |
|
199
Workday
WDAY
$42.4B
| $45.5M | 0.04% |
220,099
-280,957
| -56% | -$51.1M |
|
200
CBRE Group
CBRE
$43.9B
| $45.4M | 0.04% |
623,815
+118,086
| +23% | +$9.65M |
|
Similar funds
Jennison Associates's Q1 2023 Portfolio in Review
As of Q1 2023, Jennison Associates held 644 positions worth $109B, up 10% from $98.7B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Jennison Associates withdrew a net $3.94B in Q1 2023, closing 63 positions and reducing 280 holdings. Its most notable exit was Alcon, an estimated $1.43B position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $1.59B.
- Jennison Associates's largest Q1 2023 buy was Advanced Micro Devices: 16,272,765 shares worth $1.59B.
- Jennison Associates added most to AstraZeneca in Q1 2023, an estimated $733M increase.
- Jennison Associates's biggest Q1 2023 reduction was Estee Lauder, cutting an estimated $872M.
- Jennison Associates fully exited Alcon in Q1 2023, selling an estimated $1.43B.
- Jennison Associates's ten largest holdings make up 39% of its $109B portfolio in Q1 2023.
- Jennison Associates opened 73 new positions and closed 63 in Q1 2023.
- Jennison Associates's portfolio value rose 10% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.